Identification of a novel minor-groove DNA binder that represses mitochondrial gene expression and induces apoptosis in highly aggressive leiomyosarcoma cells
New research article (PubMed).
Curated publications, research updates, clinical trials, and educational links relevant to the broader sarcoma community.
LOI deadline: April 15, 2025
The National Leiomyosarcoma Foundation (NLMSF) invites letters of intent (LOIs) for pilot studies to launch new research trajectories in LMS, with a focus on basic and translational science. Clinical interventional trials are out of scope.
Submission contacts: matthew.hemming@umassmemorial.org and alessandra.maleddu@cuanschutz.edu
New research article (PubMed).
International multicenter analysis; Cancer (2025).
Hematology/Oncology Clinics of North America.
Clin Cancer Res. Online ahead of print.
For additional items, see our News Tracker and Clinical Trials pages.
Phase 1b/2 MB‑107: next‑gen anthracycline annamycin showed a 59.4% clinical benefit rate (n=36) with median OS 13.5 months in phase 2 (330 mg/m²). Patients achieving response or stable disease after 2 cycles had median OS 19.7 months; no cardiotoxicity reported across cohorts.
Kourti A, Kalogiannidis I, Makedou K, Georgiou E. doi: 10.3390/ijms262210952. Full research publication available via PubMed Central.
Featured publication (2021) — A collaborative paper identifying critical gaps and priorities to accelerate progress in leiomyosarcoma research and care.
Note: This library highlights selections from a larger set you provided. If you want every item included verbatim, I can import them all and add year toggles.
Imported exactly as provided to ensure every original item appears. Collapsed by default for readability.
NATIONAL LEIOMYOSARCOMA FOUNDATIONLOI deadline: April 15th, 2025
Please submit to Matthew Hemming, M.D., PhD.: matthew.hemming@umassmemorial.org and Alessandra Maleddu M.D.: alessandra.maleddu@cuanschutz.edu
Introduction: The National Leiomyosarcoma Foundation (NLMSF) is dedicated to meeting the needs of leiomyosarcoma (LMS) patients, caregivers and families through education and research. In order to facilitate advances in the treatment of LMS through research, the NLMSF is accepting research proposals for pilot studies that will launch “out of the box” ideas and new research trajectories to move the field forward.
Scope of the award/ areas of interest: All direct funds must be used to support LMS research. Proposals involving any scientific discipline are allowed including those related to biomarkers and imaging. This award was created to support basic and translational research. Other highly translational projects that are not based in a traditional wet lab may be considered (for example: in silico computational biology, radiomics, etc.); however, investigators who are considering submitting a non-traditional research project are highly encouraged to discuss the appropriateness of their project ahead of time. Clinical research (interventional trials) will not be supported by this award; however, work studying human samples and annotated data sets obtained from clinical trials is allowed. Studies requiring human samples must show documentation of IRB approval prior to awarding of funds (or document waivers if applicable).
Letter of Intent (LOI) Overview: The NLMSF seeks LOIs for research grant funding. The total award will be $50,000 per year for 2 years. Indirect costs should not exceed 10% of the total budget.
The LOI should consist of:
1) Proposed research (2 page maximum)
2) Applicant NIH Biosketch
Key Dates:
LOI due: April 15th, 2025
Invitations for full proposal sent: May 30th, 2025
Full proposal due: August 31st, 2025
Announcement: November 2025
Funding start date: January 2026
_____________________________________________________________________________________________________________________
Leiomyosarcoma Therapeutic Approaches and Future Directions (7 April 2025) available on‑line in the Hematology/Oncology Clinics of North America (22 May 2025)
https://www.sciencedirect.com/science/article/abs/pii/S0889858825000450?via%3Dihub
Emerging Role of Blood‑based Biomarkers in Sarcomas (2 April 2025) available on‑line in the Hematology/Oncology Clinics of North America (22 May 2025)
https://www.sciencedirect.com/science/article/abs/pii/S0889858825000401?via%3Dihub
Myxoid Leiomyosarcoma of the Uterus – A Case Report (2 Apr 2025) in Oncology Letters
Plain language summary
Cutaneous leiomyosarcoma (or ‘cLMS’ for short) is a type of skin tumour... These findings give us a better understanding of the biology of cLMS.
Exploration of the mutational landscape of cutaneous leiomyoma confirms FH as a driver gene https://doi.org/10.1093/bjd/ljae432
Dr. Patricia Pautier — research update in the New England Journal of Medicine
Published November 27, 2024
N Engl J Med 2024;391:2057-2058
DOI: 10.1056/NEJMc2412479
Doxorubicin–Trabectedin in Leiomyosarcoma | New England Journal of Medicine
CLINICAL TRIALS:
Randomized controlled, open‑label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first‑line treatment in patients with metastatic leiomyosarcoma. NCT06088290
Study of ADI‑PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
July 25, 2024 updated by: Polaris Group
ADI‑PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi‑Center Phase 3 Trial
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Study Overview
This is a global, multicenter, randomized, double‑blind, placebo‑controlled, parallel‑group phase 3 trial...
www.mskcc.org/cancer-care/clinical-trials/24-147
doi: 10.1200/JCO.24.00358
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)
Principle investigator: Dr. Javier Martin–Broto, esteemed member of the NLMSF International LMS Research Roundtable
https://pubmed.ncbi.nlm.nih.gov/39356980
Purpose: Doxorubicin can induce immunogenic cell death (ICD). Combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy via ICD synergy. Conclusion: The scheme is feasible and well tolerated; clinical activity is encouraging; HMGB1 supports ICD relevance. Further research is underway in LMS.
Immunotherapy in Sarcoma: Current Data and Promising Strategies
Authors: Georgina E. Wood, Christian Meyer, Florent Petitprez, Sandra P. D’Angelo
— Authors Info & Affiliations
ASCO Educational Book (May 2024)
High Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations (May 2023)
https://www.sciencedirect.com/science/article/abs/pii/S089339522300008X
NOTE: LMS discussed in this article
Targeting the Molecular and Immunologic Features of Leiomyosarcoma (31 Mar 2023)
https://www.mdpi.com/2072-6694/15/7/2099
Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas (15 Mar 2023) — MD Anderson
https://pubmed.ncbi.nlm.nih.gov/36603130/
Not All Leiomyosarcomas Are the Same: How to Best Classify LMS (8 Mar 2023) https://link.springer.com/article/10.1007/s11864-023-01067-2
Therapeutic advances in leiomyosarcoma (8 Mar 2023) — Frontiers in Oncology
https://www.frontiersin.org/articles/10.3389/fonc.2023.1149106/full
Clinical characteristics of sarcoma cases with long-term disease control on trabectedin (1 Mar 2023)
https://pubmed.ncbi.nlm.nih.gov/36857355/
Molecular subtypes of leiomyosarcoma: Moving toward a consensus (2 Nov 2022)
https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.149
CLINICAL TRIALS: TARGETED THERAPY (2 Aug 2022)
Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
https://aacrjournals.org/clincancerres/article-abstract/28/15/3225/707113/...
Phase II Clinical Trial of Eribulin–Gemcitabine... (2 Aug 2022)
A phase Ib/II study of lenvatinib + eribulin (LEADER): Efficacy updates (2 Aug 2023)
Retroperitoneal LMS Nomogram Model (3 Jul 2022)
Sounding the Alarm on Leiomyosarcoma Recurrence: Role of ctDNA (13 Jun 2022)
PRESS RELEASE NEWS — UNESBULIN for LMS (3 Jun 2022)
Surgical management strategy for LMS of IVC (3 Jun 2022)
Preclinical Modeling of LMS Identifies Susceptibility to Transcriptional CDK Inhibitors — Dr. Matt Hemming (1 Jun 2022)
Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas (13 Apr 2022)
Full publication
What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? (11 Mar 2022)
Proteomic and Metabolomic Profiling in STS (16 Feb 2022)
Surgical resection of LMS of the IVC: case series + review
Relationships between highly recurrent tumor suppressor alterations in 489 LMS
Large scale multiomic analysis suggests mechanisms of resistance to IO in LMS
Multiomic analysis to reveal distinct profiles of uterine and non‑uterine LMS
Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
PubMed | Clinical Cancer Research
Soft Tissue and Uterine Leiomyosarcoma (10 Jan 2018)